title: Down-regulation by prostaglandins of type-II phospholipase A2 expression in guinea-pig alveolar macrophages: a possible involvement of cAMP.
abstract: We have demonstrated previously that isolated guinea-pig alveolar macrophages (AM) synthesize type-II phospholipase A2 (PLA2-II) through a tumour necrosis factor-alpha (TNF-alpha)-dependent process. This synthesis is enhanced by lipopolysaccharide (LPS) and accompanied by a release of prostaglandin E2 (PGE2) into the medium. Because agents elevating intracellular cAMP, such as PGE2, have been shown to stimulate PLA2-II expression in various cell types, we investigated the modulation of PLA2-II synthesis by cAMP in AM. Surprisingly, incubation of AM with PGE2, dibutyryl-cAMP, cholera toxin or rolipram (an inhibitor of specific cAMP-phosphodiesterase) inhibited both basal and LPS-stimulated PLA2-II expression. The inhibitory effect of PGE2 was observed at concentrations similar to those released by AM. Moreover, treatment of AM with either aspirin or neutralizing PGE2 monoclonal antibody stimulated PLA2-II synthesis. These effects were closely correlated with the ability of these agents to modulate TNF-alpha release, which was decreased by dibutyryl-cAMP and exogenous PGE2, whereas neutralizing PGE2 antibody markedly increased this release. Hence, in contrast to other cell systems, we report that: (i) agents elevating intracellular cAMP levels down-regulate both basal and LPS-induced PLA2-II synthesis, (ii) prostaglandins exert a negative feedback effect on this synthesis, probably through an elevation of intracellular cAMP levels, and (iii) inhibition of TNF-alpha release may account, at least in part, for the down-regulation of PLA2-II expression by endogenously produced prostaglandins and cAMP-elevating agents.
authors.affiliation: Unité de Pharmacologie Cellulaire, Unité Associée Pasteur/INSERM U285, Institut Pasteur, 25 rue Dr. Roux 75015 Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Vial
authors.forename: L
authors.initials: L
authors.lastname: Arbibe
authors.forename: N
authors.initials: N
authors.lastname: Havet
authors.forename: C
authors.initials: C
authors.lastname: Dumarey
authors.forename: B
authors.initials: B
authors.lastname: Vargaftig
authors.forename: L
authors.initials: L
authors.lastname: Touqui
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D002772:Cholera Toxin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D015232:Dinoprostone / Q000494:pharmacology*; D015536:Down-Regulation; D054501:Group II Phospholipases A2; D006168:Guinea Pigs; D016676:Macrophages, Alveolar / Q000201:enzymology*; D008297:Male; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D014409:Tumor Necrosis Factor-alpha; D003994:Bucladesine; D002772:Cholera Toxin; D000242:Cyclic AMP; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2; D015232:Dinoprostone; D001241:Aspirin